HIV preexposure prophylaxis for adolescents and young adults.
HIV preexposure prophylaxis for adolescents and young adults.
复制标题
DOI：
10.1097/mop.0000000000000512
复制
发表时间：
2017-08
影响因子：
3.6
通讯作者：
Hsu K
中科院分区：
文献类型：
--
作者：
Allen E;Gordon A;Krakower D;Hsu K
这篇综述描述了在青少年和年轻人中每日联合应用富马酸替诺福韦(TDF)和恩曲他滨(FTC)预防HIV暴露前预防的证据。描述了当前的建议，以及关于青年使用PrEP的独特的医疗、社会经济和法律考虑。已证明，每天口服TDF-FTC有助于预防有实质性风险的成年人中新的艾滋病毒感染。有证据表明，PrEP对艾滋病毒高危青年具有保护作用，尽管依从性低正在成为有效使用的障碍。有效使用PrEP的抗逆转录病毒药物是艾滋病毒预防工作中的一项开创性发展。改善青年获得和遵守预防接种计划的机会，有可能大大降低这一人群中艾滋病毒的发病率。
This review describes the evidence for HIV pre-exposure prophylaxis (PrEP) with daily combined tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in adolescents and young adults. Current recommendations are described, as are the unique medical, socioeconomic, and legal considerations regarding the use of PrEP for youth. PrEP with daily oral TDF-FTC has been shown to help prevent new HIV infection among adults at substantial risk. Evidence suggests a protective benefit of PrEP for youth at risk for HIV, although low adherence is emerging as a barrier to effective use. Effective use of antiretrovirals for PrEP represents a seminal development in HIV prevention efforts. Improving access and adherence to PrEP for youth has the potential to substantially reduce the incidence of HIV in this population.